X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PDA-002 is a placenta-derived mesenchymal-like adherent stromal cell therapy, which is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.
Lead Product(s): PDA-002
Therapeutic Area: Musculoskeletal Product Name: PDA-002
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Biovance, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. Biovance is an intact, extracellular matrix structure that provides a natural scaffold to support the body’s wound-healing process.
Lead Product(s): Human Amniotic Membrane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Biovance
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Under the collaboration, Celularity will provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy, designed to enhance proliferation and potency against solid tumors.
Lead Product(s): Allogeneic Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2023
Details:
CYNK-001 is a cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy candidate derived from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease.
Lead Product(s): CYNK-001
Therapeutic Area: Oncology Product Name: CYNK-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
APPL-001 is a placental-derived allogeneic cell therapy, being developed for the treatment of Crohn's disease. The optimal MLASC treatment schedule is identified to be a single treatment course of two infusions seven days apart, with no further maintenance treatment required.
Lead Product(s): APPL-001
Therapeutic Area: Gastroenterology Product Name: APPL-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
CYNK-101 is a cryopreserved, off-the-shelf, allogeneic, placental CD34+ derived NK cell therapy, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant.
Lead Product(s): CYNK-101,Avelumab
Therapeutic Area: Oncology Product Name: CYNK-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
CYNK-001 is an allogeneic placental-derived unmodified NK cell. CYNK-001 may offer a benefit to patients with IAV and other viral infections, including its use a treatment for infectious disease for patients with limited treatment options.
Lead Product(s): CYNK-001
Therapeutic Area: Infections and Infectious Diseases Product Name: CYNK-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Celularity intends to use the proceeds for general corporate purposes may include research and development and clinical development costs to support the development of its cellular therapy candidate, CYNK-001 and the expansion of research and development programs.
Lead Product(s): CYNK-001,Undisclosed,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CYNK-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: YA II PN
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2022
Details:
Phase 1/2a clinical trial, evaluate safety and preliminary efficacy of CYNK-101, genetically modified NK cell therapy in combination with standard chemotherapy, trastuzumab and pembrolizumab as a first-line treatment in advanced HER2/neu positive gastric and GEJ cancer.
Lead Product(s): CYNK-101,Trastuzumab,Pembrolizumab
Therapeutic Area: Oncology Product Name: CYNK-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
USFDA granted Fast Track Designation for its cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in treatment of acute myeloid leukemia. CYNK-001 previously received orphan drug designation and fast track designation.
Lead Product(s): CYNK-001
Therapeutic Area: Oncology Product Name: CYNK-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
